Proposed Project Scope

Guanfacine for Attention-Deficit Hyperactivity Disorder (ADHD)

Date: March 2025

Background and Rationale

CDA-AMC received a request from public drug programs for a Non-Sponsored Reimbursement Review of guanfacine for attention-deficit hyperactivity disorder (ADHD).

Table I: Policy Questions

Item	Policy Question
1	Should guanfacine be publicly reimbursed for attention-deficit hyperactivity disorder (ADHD)?

Table II: Products Available in Canada

Product	Manufacturer
guanfacine hydrochloride extended-release tablets	n/a

Project Description

Table III: Project Scope

Criteria	Description
Population	Children and adolescents aged 6 to 17 years with ADHD
Intervention(s)	guanfacine hydrochloride extended-release tablets
Comparators	Placebo Stimulants Atomoxetine Clonidine Antidepressants Second-generation atypical antipsychotics
Outcomes	Clinical effectiveness (e.g., behavioural, functional, developmental, or cognitive outcomes assessed by validated scales [e.g., BRIEF-P, ADHD-RS IV, CGI-S, and CGI-I]) Patient-reported outcomes (e.g., health-related quality of life) Safety outcomes (e.g., harms, adverse events (AEs) including AEs of particular interest [e.g., hypotension and cardiovascular AEs], serious adverse event (SAEs), discontinuations due to AEs, mortality)

Table IV: Research Questions

Item	Policy Question
1	What is the effectiveness of guanfacine for ADHD?
2	What are the harms associated with guanfacine for ADHD?
3	What is the expected cost of guanfacine for ADHD vs. other reimbursed regimes?

Key Project and Protocol Components

This project will follow the Procedures for Non-Sponsored Reimbursement Reviews.

Status of the Document

This proposed project scope is being posted for information.